
TCOG癌症試驗
1. 多中心癌症臨床試驗
TCOG針對國內主要癌症推動執行由研究人員發起之跨院際學術性臨床試驗,以期快速找出適合國人之癌症治療方法,提昇癌症治療水準。TCOG邀集全國各大醫院有興趣之相關科別醫師參與合作癌症研究計畫,執行個案篩檢、收案、計畫治療及追蹤存活狀態。目前已完成T1188乳癌、T1488淋巴癌、T1788軟組織肉瘤、T1592小細胞肺癌、T1394晚期鼻咽癌、T1495淋巴癌、T1296胃淋巴癌、胃腺癌病患表格登錄、T1297肝癌術後、T1899子宮頸抹片篩檢、T2201胃癌、T1E01子宮頸癌、T3202膽道癌、T1802攝護腺癌、T2399口腔癌、T1401淋巴癌、大腸直腸癌病患表格登錄、T1399口腔癌、T2202肝癌、T1202大腸直腸癌、T1204胰臟癌、T1303鼻咽癌、T1405 淋巴癌、T1406淋巴瘤、T1706軟組織惡性肉瘤、T1209肝癌、T1206肝癌、T2207大腸癌、T1309口腔癌、T1210膽臟癌、T1306口腔癌、T2209胰臟癌、T3211胃癌、T2211胃腸道基質瘤、T3207胰臟癌、T3206胃淋巴瘤、T1211胰臟癌、T1408淋巴癌、TG1308膽道癌、T1313鼻咽癌、T2312鼻咽癌、T3214膽道癌、T3212胰臟癌、T1Z14神經內分泌瘤、T2212胰臟癌、T1914白血病、T5217胰臟癌、T2214胃淋巴瘤、T1217胰臟癌、T1214胃腸道基質瘤暨神經內分泌腫瘤、T2317頭頸癌、T1317鼻咽癌、T3217膽道癌、T1216消化道癌、T1219膽道癌、TG1709胰臟癌、T2217肝癌、T1519肺癌等五十八個研究計畫之個案收錄,總計收錄9,287例個案,已發表34篇研究論文。目前持續執行收案中之計畫計有T2219肝癌、T1420淋巴癌、T2420淋巴癌、T1220食道癌、T2221胃腸胰神經內分泌腫瘤、T5221胰臟癌、T2220胃食道癌、T1421淋巴癌、T1222膽道癌、T2222胃腸胰神經內分泌癌等治療型,以及T1218胃腸道基質瘤、T6221胃腸道基質瘤、T1521肺癌、T1221胃腸道基質瘤、T3221膽道癌、T4221食道癌、T2322甲狀腺癌、T1322口咽癌、T4222肝癌、T3322腦癌、T1622黑色素瘤、T1822泌尿道癌等NGS登錄型,共計22個研究計畫,至2023年2月總計收案2,573例;含已結束的計畫尚有2,403例個案執行計畫治療中、持續追蹤168例個案存活狀況。2023年尚有T3222膽道癌、T1223胃癌等數個新計畫將開始送審執行。 |
![]() TCOG歷年計畫癌別 |
癌症藥物及治療方式日新月異,需通過嚴謹的各期臨床試驗後方得以證實其療效。癌症病患必須符合臨床試驗的篩選條件,方能加入該試驗參與計畫治療;由於病患之身體與疾病狀況可能有相當之差異,有意願參與癌症臨床試驗的病患應與您的主治醫師討論洽詢,選擇最符合病患利益之治療方式。
執行中研究計畫 (更新至Feb. 2023)
已結束之研究計畫
代號 | 計畫書 | 主持人 | 計畫執行期 | 實際收案數 |
---|---|---|---|---|
T1188 | Phase II Study of Weekly CAF for Advanced Breast Cancer. | Wei-Shou Hwang | 1988.10 ~ 1994.12 | 107 |
T1488 | Prospective Study of T and B Cell NHL by Using CHOP. | Ann-Lii Cheng | 1988.9 ~ 1994.12 | 213 |
T1788 | Phase II Trial of VIP in Advanced Soft Tissue Sarcoma. | Wei-Shou Hwang | 1988.7 ~ 1994.12 | 90 |
T1592 | Evaluation of Dose Optimization of Carboplatin for SCLC. | Jang-Yang Chang | 1992.2 ~ 1995.5 | 40 |
T1394 | Phase III Study of R/T vs. CCRT in Advanced NPC. | Kwan-Hwa Chi | 1994.11 ~ 1999.7 | 158 |
T1495 | Phase III Study of Steroid-containing vs. Steroid-free Chemotherapy for HBV Carriers with Non-Hodgkin’s Lymphoma. | Ann-Lii Cheng, Pei-Jer Chen |
1995.11 ~ 2000.5 | 50 |
T1296 | Eradication of HP in the Management of Low-grade MALToma. | Li-Tzong Chen | 1996.3 ~ 1999.4 | 41 |
A1293 | Gastric Adenocercinoma Registry in Surgery and Pathology. | Chew-Wun Wu | 1998.6 ~ 2000.12 | 1386 |
T1297 | Phase III Adjuvant IFN vs Conservative Tx for Post OP HCC. | Li-Tzong Chen, Pei-Jer Chen |
1997.10 ~ 2003.4 | 268 |
T1899 | HPV Survey in CIN for LSIL Cases. | Tang-Yaun Chu, Chi-An Chen, Tzer-Ming Chen |
1999.8 ~ 2004.2 | 1331 |
T2201 | Phase III Study in PostOP Adjuvant CCRT for Stage III & IVa Adeno- carcinoma of Stomach. | Jang-Yang Chang | 2001.4 ~ 2004.3 | 14 |
T1E01 | PostOP Adjuvant Therapy for Stage Ib-IIa Cervical Carcinoma with Pelvic LN Meta. | Chyong-Huey Lai | 2002.2 ~ 2004.3 | 4 |
T1802 | Phase II THADO for Prostate Cancer. | Ruey-Kuen Hsieh | 2002.10 ~ 2004.7 | 30 |
T3202 | Phase II Palliative C/T for Biliary Tract Cancer. | Chiun Hsu | 2002.7 ~ 2004.9 | 50 |
T2399 | Phase III Adjuvant CCRT for High-risk Oral Cavity Cancer. | Mow-Ming Hsu, Ruey-Long Hong |
1999.8 ~ 2004.11 | 161 |
T1401 | Phase III Oral Anti-HBV Prophylaxis for HBV Carrier with Non-Hodgkin’s Lymphoma. | Ann-Lii Cheng, Pei-Jer Chen |
2001.10 ~ 2005.4 | 52 |
HNPCC | Heritable Colorectal Cancer Registry. | Reiping Tang | 2002.5 ~ 2006.12 | 817 |
T1399 | Phase III Chemoprevention Tx vs Placebo for Oral Cavity Cancer. | Mow-Ming Hsu, Ruey-Long Hong |
1999.4 ~ 2005.7 | 342 |
T2202 | Phase III Thado vs Placebo for Advanced HCC. | Li-Tzong Chen | 2003.2 ~ 2007.7 | 16 |
T1202 | Phase II Adjuvant C/T for High-risk Colon Cancer. | Tsai-Shen Yang | 2002.4 ~ 2008.1 | 162 |
T1204 | Phase II Induction C/T + CCRT for Locally Advanced Pancreatic Cancer. | Hui-Ju Ch’ang, Li-Tzong Chen |
2004.11 ~ 2008.8 | 50 |
T1303 | Phase III Induction C/T +CCRT vs CCRT for Stage IV NPC. | Ruey-Long Hong, Mow-Ming Hsu, Cheng-Hsu Wang |
2003.8 ~ 2009.8 | 480 |
T1405 | Phase II CCRT for NK T-cell Lymphoma. | Ming-Chih Chang | 2006.5 ~ 2009.9 | 33 |
T1406 | Phase II High Dose MTX + Steroid and Whole Brain R/T with Temozolomide for CNS Lymphoma. | Ching-Hung Lin, Ann-Lii Cheng |
2006.11 ~ 2009.10 | 4 |
T1706 | Phase II C/T with Gemcitabine & Docetaxel for Soft Tissue Sarcoma or GI Stromal Tumor. | Chung-Huang Chan | 2006.12 ~ 2010.1 | 58 |
T1209 | Phase I/II sorafenib + thalidomide in HCC. | Chung-Huang Chan | 2009.8 ~ 2010.1 | 3 |
T1206 | Phase III Adjuvant Oral Anti-HBV Tx for Post OP HCC. | Li-Tzong Chen, Pei-Jer Chen |
2007.4 ~ 2010.8 | 117 |
T1309 | Phase II Study of Neoadjuvant Bio-C/T with CPC Followed by Bio-R/T in High-risk OSCC. | Jang-Yang Chang, Sen-Tien Tsai |
2009.9~2011.5 | 47 |
T2207 | Phase II Trial Celecoxib with PreOP CCRT for Locally Advanced Rectal Cancer. | Ling-Wei Wang | 2007.7 ~ 2011.6 | 55 |
T1210 | Randomized Phase II Study of GEMOX With or Without Cetuximab in BTC. | Li-Tzong Chen | 2010.12 ~ 2012.5 | 122 |
T1306 | Phase II/III Adjuvant Anti-Angiogenesis Tx for High-risk Oral Cavity Cancer. | Ruey-Long Hong | 2007.5 ~ 2012.12 | 150 |
T2209 | Phase II Randomized Study of C/T Followed by CCRT in Locally Advanced Pancreatic Cancer. | Hui-Ju Ch’ang, Yan-Shen Shan |
2009.11 ~ 2013.1 | 15 |
T3211 | Phase II Study Using Genetic Polymorphisms of Drug in Patients with Gastric Cancer. | Yee Chao, Ming-Huang Chen |
2012.3 ~ 2014.11 | 51 |
T2211 | Phase II Study of Weekly AUY922 for Advanced GIST. | Li-Tzong Chen, Nai-Jung Chiang |
2011.10 ~ 2015.2 | 29 |
T3206 | Phase II Triple-Treatment for Low & High Grade MALToma. | Li-Tzong Chen | 2006.10 ~ 2015.5 | 47 |
T3207 | Phase III Adjuvant Gemcitabine vs. Gemcitabine + CCRT in Pancreatic Cancer. | Tsann-Long Hwang, Hui-Ju Ch’ang |
2009.2 ~ 2015.7 | 147 |
T1408 | Chemotherapy-Induced Hepatitis B Reactivation in Lymphoma Patients with Resolved HBV Infection: A Prospective Study. | Chiun Hsu | 2009.6 ~ 2011.12 2014.3 ~ 2015.12 |
154 + 48 |
T1211 | Phase I/II Trial of SLOG Therapy in Metastatic Pancreatic Cancer. | Li-Tzong Chen, Kun-Chih Tsai |
2012.4 ~ 2015.12 | 73 |
TG1308 | S-1 in Combination with Gemcitabine for Patients with Advanced Biliary Tract Cancer. | Li-Tzong Chen | 2015.5 ~ 2016.6 | 51 |
T1313 | Phase III Trial in NPC with Post- radiation Detectable Plasma EBV DNA. | Jin-Ching Lin | 2014.12 ~ 2016.12 | 10 |
T2312 | The Effect of EGCG on Virus Reactivation in Post- radiation NPC Patients without Detectable EBV DNA. | Jin-Ching Lin, Jen-Yang Chen, Sen-Tien Tsai |
2013.4 ~ 2017.10 | 353 |
T3214 | Phase II Trial of LDK378 as Therapy in ROS1 and /or ALK Over-expressed Advanced Intrahepatic or Hilar Cholangiocarcinoma. | Li-Tzong Chen, Hui-Ju Ch’ang |
2015.9 ~ 2017.12 | 9 |
T3212 | The Clinical Significance of Bio-markers in Pancreatic Cancer Patients. | Hui-Ju Ch’ang, Li-Tzong Chen |
2012.12 ~2018.3 | 270 |
T1Z14 | Phase II Study of TLC388 as Second-line Treatment for poorly-differentiated NET Patients. | Yee Chao, Ming-Huang Chen, Hui-Jen Tsai |
2015.7 ~ 2018.5 | 23 |
T2212 | Randomized Two Arms Phase II Study of Induction Chemotherapy Followed by CCRT in Locally Advanced Pancreatic Cancer. | Hui-Ju Ch’ang, Yen-Shen Shen |
2013.7 ~ 2019.1 | 55 |
T1914 | Molecular Features Underlying Ethnic Differences in Survival of CLL Patients in Taiwan. | Hwei-Fang Tien, Shang-Ju Wu |
2015.11 ~ 2019.1 | 255 |
T5217 | A Phase II Randomized Study of SLOG vs mFOLFIRINOX as the First-line Treatment in Locally Advanced Unresectable or Metastatic Pancreatic Cancer | Li-Tzong Chen, Nai-Jung Chiang, Yen-Shen Shen |
2018.3 ~ 2019.11 | 130 |
T2214 | First-line Antibiotic Therapy for Early-stage HP(+) Gastric Pure DLBCL. | Sung-Hsin Kuo, Li-Tzong Chen |
2015.4 ~ 2020.3 | 17 |
T1217 | Phase II Trial of Biweekly S-1, Leucovorin and Gemcitabine (GSL) in Elderly Patients with Locally Advanced or Metastatic Pancreatic Adenocarcinoma | Li-Tzong Chen, Li-Yuan Bai |
2018.7 ~ 2020.3 | 49 |
T1214 | Multi-center Registration Study for Gastroentero- Pancreatic NET in Taiwan | Li-Tzong Chen, Yen-Shen Shen, Hui-Jen Tsai |
2014.1 ~2020.4 | 600 |
T2317 | Phase 2 Study of Nanoliposomal Irinotecan (nal-IRI, PEP02, MM-398, Onivyde®) with 5-FU and Leucovorin in Squamous Cell Carcinoma (SCC) of Head & Neck and Esophagus after Prior Platinum-based Chemotherapy or Chemoradiotherapy | Li -Yuan Bai, Nai-Jung Chiang |
2018.12 ~ 2020.5 | 59 |
T1317 | Pembrolizumab for Nasopharyngeal Carcinoma Patients with Detectable Plasma Epstein-Barr Virus DNA but Without Clinically Detectable Residual Diseases and/or Metastases After Curative Chemoradiation – A Single Arm Phase II Trial | Hsiang-Fong Kao, Kwang-Yu Chang |
2019.1 ~ 2020.5 | 2 |
T3217 | Phase II Randomized Trial of S-1, Leucovorin, Oxaliplatin and Gemcitabine (SLOG) vs Gemcitabine and Cisplatin (GC) in Locally Advanced or Metastatic Biliary Tract Cancer | Li-Tzong Chen, Nai-Jung Chiang |
2018.4 ~ 2020.6 | 92 |
T1216 | An Open-Label Phase I, Dose-Escalation Study of Biweekly Abraxane in Combination with Oxaliplatin and Oral S-1/LV, the SOLAR Regimen, as First-line Chemotherapy in Patients with Advanced Gastric, Pancreatic and Biliary Cancers | Li-Tzong Chen | 2018.2 ~ 2020.11 | 19 |
T1219 | A Study of Nivolumab combination Gemcitabine and S1 as First Line Treatment in Patients with Advanced Biliary Tract Cancer | Ming-Huang Chen, Nai-Jung Chiang |
2019.12 ~ 2020.12 | 48 |
TG1709 | A phase II study of S-1 Adjuvant Chemotherapy in Patients with Resected Pancreatic Cancer in Taiwan | Li-Tzong Chen | 2019.07 ~ now | 36 |
T2217 | Nivolumab plus ipilimumab as neoadjuvant therapy for hepatocellular carcinoma (HCC) | Chiun Hsu | 2019.1 ~ 20022.4 | 47 |
T1519 | A Phase 2 trial of durvalumab (MEDI4736) and tremelimumab with chemotherapy in metastatic EGFR mutant non-squamous non-small cell lung cancer (NSCLC) following progression on EGFR Tyrosine Kinase Inhibitors (TKIs) (ILLUMINATE) | Chih-Hsin Yang, Hui-Jen Tsai |
2020.04 ~ 2022.12 | 50 |
2. 國際合作癌症臨床試驗
TCOG於2006年加入為國際乳癌組織 (Breast International Group, BIG) 會員,並參與其所推動之跨國際乳癌臨床試驗。歷年來TCOG代表台灣參與完成HERA、NeoA、LTTO、ALTTO、APHINITY、PALLAS、Olympia等六個乳癌國際研究計畫,總計全球收錄26,013例個案,其中台灣收錄742例。進行中之ALEXIMp030計畫台灣共計13家醫院參與,已進案70例;全球總進案2,199例。
BIG計畫歷年來已發表HERA、NeoALTTO、APHINITY、Olympia計畫共計8篇研究成果期刊論文。其中HERA計畫分別於2005年N Engl J Med期刊和2010年J Clin Oncol期刊、APHINITY計畫於2017年N Engl J Med期刊和2021年J Clin Oncol期刊和2023年ESMO Open期刊、Olympia計畫於2021年N Engl J Med期刊和2022年Ann Oncol期刊中台灣各有一位醫師列名共同作者;NeoALTTO計畫於2012年Lancet期刊中台灣有二位醫師列名共同作者。NeoALTTO計畫台灣是23個地區收案最多的國家、委員亦為收案最多的醫師之一;APHINITY計畫亞太區收案情形台灣排名第三,試驗單位部分北榮收案排名第五、台大第六位、中榮並列第十位。
A. On-going Clinical Protocols:
Protocol | Date Activated | Taiwan Sites | Taiwan Cases | Global Cases |
---|---|---|---|---|
ALEXIMp030 | 2018.7 ~ now | 10 | 70 | 2,199 |
B. Finished Protocols:
Protocol | Date Activated | Taiwan Sites | Taiwan Cases | Global Cases |
---|---|---|---|---|
Olympia | 2014.4 ~ 2019.5 | 11 | 10 | 1,824 |
PALLAS | 2015.10 ~ 2018.11 | 5 | 31 | 5,552 |
APHINITY | 2011.11 ~ 2013.8 | 7 | 170 | 4,805 |
ALTTO | 2007.5 ~ 2011.6 | 8 | 374 | 8,283 |
NeoALTTO | 2008.1 ~ 2009.11 | 7 | 57 | 450 |
HERA | 2001.11 ~ 2005.3 | 4 | 100 | 5,099 |